Does Dr. RONAN KELLY have financial conflicts of interest?

Dr. RONAN KELLY (MD) has received a total of $1,082,714 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $1,035,911 in personal promotional payouts (consulting, meals, travel) and $46,803 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. RONAN KELLY?

According to CMS Open Payments data, Dr. RONAN KELLY received funding from E.R. SQUIBB & SONS, L.L.C ($469,220), ASTELLAS PHARMA US ($132,460), and DAIICHI SANKYO ($119,895).

Does Dr. RONAN KELLY receive research grants or speaking fees?

Dr. RONAN KELLY has received $1,035,911 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $46,803 in clinical research grants.

DR. RONAN KELLY

MDReal-Time Hydrated

Specialty: Internal Medicine, Medical Oncology

Practice Location: DALLAS, TX 75246

NPI Number: 1477846715

LIFETIME INDUSTRY VALUE

$1,082,714

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. KELLY is a verified Internal Medicine, Medical Oncology practitioner based in DALLAS, TX.

Between 2021 and 2025, Dr. KELLY had an overall industry promotional and research financial footprint of $1,082,714 as recorded in the federal CMS Open Payments database.

$1,035,911 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$46,803 was allocated to sponsored clinical trials and medical research activities.

Dr. KELLY's primary funding source is E.R. SQUIBB & SONS, L.L.C, which accounts for $469,220 (representing 43.3% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

E.R. SQUIBB & SONS, L.L.C

Rank 1

$469,220

43.3%

ASTELLAS PHARMA US

Rank 2

$132,460

12.2%

DAIICHI SANKYO

Rank 3

$119,895

11.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.